DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests

DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests
Six regions in the non-coding parts of the DNA that surround FOXA1, a major prostate cancer driver, may be therapeutic targets for lowering the amount of this cancer-promoting protein — and potentially impairing the growth of prostate cancer cells, a new study suggests. FOXA1 is involved in a variety of other cancers, but its three-dimensional structure has largely hampered the development of effective inhibitors. The newly discovered regions may present a good alternative to modulate FOXA1 activity, the researchers said. Titled “Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer,” the study was published in Nature.  A protein found in many parts of the body, FOXA1 has been specifically implicated in the development of prostate cancer. Mutations in the FOXA1 gene, and the DNA sequence that surrounds the gene — which controls the levels of FOXA1 protein — are found in men with early and advanced prostate cancers. The function of FOXA1 is to bind directly to DNA, allowing genes to be read and proteins to be produced — all supporting the normal function of a cell. However, mutations leading to an abnormal FOXA1, or its overproduction, can lead to aberrant function and the development of cancer.  Despite the knowledge that FOXA1 plays a critical role in prostate cancer, and other cancers such as breast and lung cancers, therapeutic strategies to block its activity are lacking due to difficulties in directly inhibiting FOXA1 activity. An alternative therapeutic approach now being explored is to block the overproduction of FOXA1.  As FOXA1 production, or expression, is controlled by the DNA that surrounds the gene — the non-coding region — analysis of these regions may provide insight into the regu
Subscribe or to access all post and page content.